Eyetech To Announce Second Quarter 2005 Financial Results On July 27, 2005

Eyetech To Announce Second Quarter 2005 Financial Results On July
27, 2005 


NEW YORK, July 15  /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc.
(NASDAQ:EYET), today announced that it plans to report second quarter 2005
financial results on Wednesday, July 27, 2005 after the U.S. financial markets
close.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGO )

Eyetech's senior management will hold a conference call and webcast to discuss
the results and provide a company update on Thursday, July 28, 2005 at 11:00
a.m. Eastern Time.

Live audio of the conference call will be available to investors, members of
the news media and the general public by dialing 888-275-0218 (in the United
States) or 706-679-7756 (internationally).  A playback of the call will be
available through August 4, 2005 by dialing 800-642-1687, passcode 7698407 (in
the United States) or 706-645-9291, passcode 7698407 (internationally). To
access the call by live webcast, please log on to the Investor Relations
section of our corporate website at http://www.eyetech.com/.  An archived
version of the webcast will be available at the same location through August 4,
2005.

About Eyetech Pharmaceuticals, Inc.

Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes
in the development and commercialization of novel therapeutics to treat
diseases of the eye.  Eyetech's initial focus is on diseases affecting the back
of the eye.  Eyetech is commercializing and further developing Macugen(R)
(pegaptanib sodium injection) with Pfizer Inc for the treatment of neovascular
AMD.  Macugen is also being studied for other indications including diabetic
macular edema and retinal vein occlusion. 

http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGO

http://photoarchive.ap.org/

DATASOURCE: Eyetech Pharmaceuticals, Inc.



CONTACT:  Investors - Glenn Sblendorio, Chief Financial Officer,

T: [phone], F: [phone], E-mail: ;

or Media - Chris Smith, Public Relations & Corporate Communications,

T: [phone], F: [phone], E-mail: , both

of Eyetech Pharmaceuticals, Inc.



Web site:  http://www.eyetech.com/ 

Copyright